These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 26340361)

  • 1. Overcoming barriers in Pseudomonas aeruginosa lung infections: Engineered nanoparticles for local delivery of a cationic antimicrobial peptide.
    d'Angelo I; Casciaro B; Miro A; Quaglia F; Mangoni ML; Ungaro F
    Colloids Surf B Biointerfaces; 2015 Nov; 135():717-725. PubMed ID: 26340361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers.
    Ungaro F; d'Angelo I; Coletta C; d'Emmanuele di Villa Bianca R; Sorrentino R; Perfetto B; Tufano MA; Miro A; La Rotonda MI; Quaglia F
    J Control Release; 2012 Jan; 157(1):149-59. PubMed ID: 21864595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biocompatible antimicrobial colistin loaded calcium phosphate nanoparticles for the counteraction of biofilm formation in cystic fibrosis related infections.
    Iafisco M; Carella F; Degli Esposti L; Adamiano A; Catalucci D; Modica J; Bragonzi A; Vitali A; Torelli R; Sanguinetti M; Bugli F
    J Inorg Biochem; 2022 May; 230():111751. PubMed ID: 35151101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections.
    Günday Türeli N; Torge A; Juntke J; Schwarz BC; Schneider-Daum N; Türeli AE; Lehr CM; Schneider M
    Eur J Pharm Biopharm; 2017 Aug; 117():363-371. PubMed ID: 28476373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients.
    Sans-Serramitjana E; Fusté E; Martínez-Garriga B; Merlos A; Pastor M; Pedraz JL; Esquisabel A; Bachiller D; Vinuesa T; Viñas M
    J Cyst Fibros; 2016 Sep; 15(5):611-8. PubMed ID: 26708265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nano into Micro Formulations of Tobramycin for the Treatment of Pseudomonas aeruginosa Infections in Cystic Fibrosis.
    Porsio B; Cusimano MG; Schillaci D; Craparo EF; Giammona G; Cavallaro G
    Biomacromolecules; 2017 Dec; 18(12):3924-3935. PubMed ID: 29111673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
    J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dry powder inhalation containing muco-inert ciprofloxacin and colistin co-loaded liposomes for pulmonary P. Aeruginosa biofilm eradication.
    Wang J; Guo Y; Lu W; Liu X; Zhang J; Sun J; Chai G
    Int J Pharm; 2024 Jun; 658():124208. PubMed ID: 38723731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors.
    Nafee N; Husari A; Maurer CK; Lu C; de Rossi C; Steinbach A; Hartmann RW; Lehr CM; Schneider M
    J Control Release; 2014 Oct; 192():131-40. PubMed ID: 24997276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large Porous Particles for Sustained Release of a Decoy Oligonucelotide and Poly(ethylenimine): Potential for Combined Therapy of Chronic Pseudomonas aeruginosa Lung Infections.
    d'Angelo I; Perfetto B; Costabile G; Ambrosini V; Caputo P; Miro A; d'Emmanuele di Villa Bianca R; Sorrentino R; Donnarumma G; Quaglia F; Ungaro F
    Biomacromolecules; 2016 May; 17(5):1561-71. PubMed ID: 27002689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spray-freeze-dried inhalable composite microparticles containing nanoparticles of combinational drugs for potential treatment of lung infections caused by Pseudomonas aeruginosa.
    Yu S; Pu X; Ahmed MU; Yu HH; Mutukuri TT; Li J; Zhou QT
    Int J Pharm; 2021 Dec; 610():121160. PubMed ID: 34624446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyanion-tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
    Craparo EF; Porsio B; Schillaci D; Cusimano MG; Spigolon D; Giammona G; Cavallaro G
    Nanomedicine (Lond); 2017 Jan; 12(1):25-42. PubMed ID: 27879162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanometric ion pair complexes of tobramycin forming microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
    Sardo C; Di Domenico EG; Porsio B; De Rocco D; Santucci R; Ascenzioni F; Giammona G; Cavallaro G
    Int J Pharm; 2019 May; 563():347-357. PubMed ID: 30935918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
    Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
    J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward Repositioning Niclosamide for Antivirulence Therapy of Pseudomonas aeruginosa Lung Infections: Development of Inhalable Formulations through Nanosuspension Technology.
    Costabile G; d'Angelo I; Rampioni G; Bondì R; Pompili B; Ascenzioni F; Mitidieri E; d'Emmanuele di Villa Bianca R; Sorrentino R; Miro A; Quaglia F; Imperi F; Leoni L; Ungaro F
    Mol Pharm; 2015 Aug; 12(8):2604-17. PubMed ID: 25974285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(lactide- co-glycolide) Nanoparticles for Prolonged Therapeutic Efficacy of Esculentin-1a-Derived Antimicrobial Peptides against Pseudomonas aeruginosa Lung Infection: in Vitro and in Vivo Studies.
    Casciaro B; d'Angelo I; Zhang X; Loffredo MR; Conte G; Cappiello F; Quaglia F; Di YP; Ungaro F; Mangoni ML
    Biomacromolecules; 2019 May; 20(5):1876-1888. PubMed ID: 31013061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alginate lyase immobilized chitosan nanoparticles of ciprofloxacin for the improved antimicrobial activity against the biofilm associated mucoid P. aeruginosa infection in cystic fibrosis.
    Patel KK; Tripathi M; Pandey N; Agrawal AK; Gade S; Anjum MM; Tilak R; Singh S
    Int J Pharm; 2019 May; 563():30-42. PubMed ID: 30926526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved effect of amikacin-loaded poly(D,L-lactide-co-glycolide) nanoparticles against planktonic and biofilm cells of Pseudomonas aeruginosa.
    Sabaeifard P; Abdi-Ali A; Gamazo C; Irache JM; Soudi MR
    J Med Microbiol; 2017 Mar; 66(2):137-148. PubMed ID: 28260589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.